Pricing an inspection history: sterile capacity and what a buyer inherits

In sterile pharmaceutical manufacturing the inspection record of a site is a priced asset. A buyer acquiring a facility inherits the observations raised against it, the commitments given in response, and the timetable the supervisory authority in that jurisdiction is working to. None of those transfer at book value. Investment Banking has advised on eleven processes involving sterile capacity since 2021, and the difference in outcome between clean and encumbered sites has been consistent across all of them.

Targets with no open observations cleared at a median of 9.4 times operating profit. Targets carrying an open major observation cleared at 6.8 times. The gap of 2.6 turns is much larger than the cost of fixing the problem: median remediation across the sites examined cost US$4.1 million and took 16 months, against a median enterprise value of US$96 million. Buyers are not pricing the repair. They are pricing the possibility that the repair fails.

That possibility is real and it does not diversify away. A site under a remediation commitment is a site the authority returns to. A second adverse finding on a return visit moves the range of outcomes from cost to closure, and a closed sterile line cannot be replaced by buying capacity elsewhere at short notice, because any replacement must itself be qualified for the product. The buyer is underwriting a low-probability outcome with a very large loss behind it.

Escrow is the usual answer and it is a poor one. Between 8 and 15 per cent of consideration held for 24 months compensates a buyer for cost but not for the loss of a line. It also fixes the proceeds of the seller at the low end of the range for two years, during which the seller has no ability to influence the remediation it is being held against. In four of the eleven processes the escrow was the last point of disagreement to be settled.

The advice of the division is to remediate before the process rather than during it. One client deferred a sale by eleven months, closed 34 open observations, obtained a clean re-inspection and sold at 9.1 times against an indicative 6.9 times before the deferral. The eleven months cost about US$3.8 million in remediation and delay. The change in price was about US$21 million. The arithmetic is rarely as close as a seller fears.

One case runs the other way. Where the difficulty lies in the product rather than in the plant, the observations will not close on any timetable the seller controls, and delay converts a discount into a failed process. Two of the eleven targets fell into that category and both were sold with the discount taken openly and early. Distinguishing the two cases is the whole of the work, and it is done by reading the observations rather than the summary.

Published 2025-11-11 by the Investment Banking division. Research is prepared for eligible counterparties and does not constitute advice.